Therapeutic Area

HIV

Therapeutic area intelligence for HIV with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Companies

ClinicalJune 20, 2026

A new study aims to characterize intestinal tissue-resident memory T cells in HIV-1 patients on ART, focusing on their role in viral persistence.

RegulatoryJune 17, 2026

Merck's IDVYNSO, a two-drug regimen, has been approved by the FDA for adults with virologically suppressed HIV-1.

CompetitiveJune 16, 2026

Gilead and Merck announced positive topline results from two Phase 3 studies for Islatravir/Lenacapavir, a novel oral HIV treatment.

No catalysts indexed for this entity yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.